The influence of physicians' guideline compliance on patients' statin adherence: A retrospective cohort study

https://doi.org/10.1016/j.amjopharm.2005.12.001Get rights and content

Background:

National cholesterol management guidelines recommend regular follow-up of patients and annuallipid evaluations to promote adherence to statin therapy.

Objective:

This study examined the relationship between primary care physicians' (PCPs') compliance with primary care guidelines and patients' adherence to statin therapy.

Methods:

A retrospective cohort study was conducted among statin users aged ≥50 years who had an assigned PCPat a Veterans Affairs Medical Center. The dependent variable was statin adherence by patients over 24 months. Computerized pharmacy, laboratory, and medical records were used to measure PCPs' compliance with 4 recommendations in national cholesterol management guidelines: (1) lipid-lowering drug (LLD) initiation; (2) 8-week follow-up visit after an initial LLD prescription; (3) 6- or 12-month follow-up visit for established LLD users; and (4) annual lipid evaluation. Multilevel, multivariable regression models were used to estimate the effects of PCPs' guideline compliance on patients' adherence while controlling for patients' demographic characteristics, comorbid conditions, and pharmacotherapy factors.

Results:

The sample included 82 PCPs caring for 4707 patients. The mean statin adherence rate was 83.9%. Anincrease in the annual lipid evaluation rate resulted in an increase in patients' adherence (P − 0.037). Black race and higher statin dose negatively influenced patients' adherence (both, P < 0.001). The effects of PCPs' compliance rates were not homogeneous across race. Specifically, the 8-week follow-up visit rate after initial LLD prescription was significantly associated with improved statin adherence among the black subpopulation only.

Conclusions:

Patients' adherence to statin therapy was influenced by their PCPs' compliance with cholesterol management guidelines. Efforts should be made to align PCPs' practice with published guidelines for optimal statin therapy, especially for vulnerable subpopulations of patients.

References (52)

  • StilleyC.S. et al.

    Psychological and cognitive function: Predictors of adherence with cholesterol lowering treatment

    Ann Behav Med

    (2004)
  • NissenS.E. et al.

    Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, andcoronary artery disease

    N Engl J Med

    (2005)
  • MRC/ BHF Heart Protection Study of cholesterol loweringwith simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial

    Lancet

    (2002)
  • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)

    Lancet

    (1994)
  • CheungB.M. et al.

    Metaanalysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes

    Br J Clin Pharmacol

    (2004)
  • MavigliaS.M. et al.

    Using an electronic medical record to identify opportunities to improve compliance with cholesterol guidelines

    J Gen Intern Med

    (2001)
  • AbookireS.A. et al.

    Use and monitoring of “statin” lipid-lowering drugs compared with guidelines

    Arch Intern Med

    (2001)
  • BennerJ.S. et al.

    Long-term persistence in use of statin therapy in elderly patients

    JAMA

    (2002)
  • AvornJ. et al.

    Persistence of use of lipid-lowering medications: A cross-national study

    JAMA

    (1998)
  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults

    Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

    JAMA

    (2001)
  • PearsonT.A. et al.

    The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

    Arch Intern Med

    (2000)
  • McBrideP. et al.

    Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease

    Arch Intern Med

    (1998)
  • JackeviciusC.A. et al.

    Adherence with statin therapy in elderly patients with and without acute coronary syndromes

    JAMA

    (2002)
  • EllisJ.J. et al.

    Suboptimal statin adherence and discontinuation in primary and secondary prevention populations

    J Gen Intern Med

    (2004)
  • SchectmanG. et al.

    Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals

    Am J Med

    (1996)
  • SokolM.C. et al.

    Impact of medication adherence on hospitalization risk and healthcare cost

    Med Care

    (2005)
  • Cited by (21)

    • Medication oversupply in patients with diabetes

      2015, Research in Social and Administrative Pharmacy
      Citation Excerpt :

      This is notably less than reported in prior studies of Veterans,22,39,41 Medicaid enrollees,42 and other underserved patients receiving care in safety-net systems,14–16 where oversupply was observed in ∼25–50% of patients taking these classes. The lower prevalence of oversupply observed in this study of 2006–2008 claims, compared to past studies using older data (i.e., 1990s and early 2000s),14–16,22,39,41,42 may reflect payers' increased use in recent years of computerized utilization management systems designed to prevent dispensing of oversupplies. Such computerized systems identify early refills and duplicate prescriptions within a subclass when patients attempt to obtain them at pharmacies.

    • Access to heart failure care post emergency department visit: Do we meet established benchmarks and does it matter?

      2013, American Heart Journal
      Citation Excerpt :

      In our study, the adherence to the recommended 2-week timeline for consultation subsequent to an ED visit was 30.2%. This is lower than the 39% adherence rate with respect to a guideline of 8-week follow-up of patients who were newly prescribed statin therapy.27 The authors of this latter study suggest that the low adherence to this guideline stems from difficulty to schedule patients within the “short” timeframe of 8 weeks.

    View all citing articles on Scopus
    View full text